- » Ask the Expert
- » ATE Questions
- » Possible effects of gastric bypass surgery on psoriasis in an obese patient
Possible effects of gastric bypass surgery on psoriasis in an obese patient
What recommendations do you have for the treatment of an obese patient with psoriasis and psoriatic arthritis who is considering gastric bypass surgery? Will it improve the psoriatic disease? Are there any risks related to the psoriatic disease?
Please read the CME information below and click Begin Activity at the bottom of this page to continue to the answer.
Release date: October 2009
Expiration date: October 31, 2010
Estimated time to complete activity: 15 minutes
No longer available for CME credit
Sponsored by Curatio CME Institute
Support for this activity has been provided through educational grants from Amgen and Genentech.
Questions submitted to Ask the Expert and the answers provided by the members of our panel will be posted on PsoriasisTx.com along with supporting literature where appropriate.
This activity has been designed to meet the educational needs of dermatologists and other health care professionals involved in the care of patients with psoriasis.
Each Ask the Expert activity will have one of the learning objectives listed below associated with it.
Upon completion of this activity, participants should be able to:
- Describe the current standard of treatment for moderate to severe psoriasis, including the use of traditional and biologic systemic agents
- Recognize the clinical effect of psoriasis on the development of cardiovascular comorbidities
- Distinguish mechanisms of therapeutic intervention based on the pathophysiology of and cellular pathways associated with psoriasis
- Assess the long-term safety and monitoring associated with biologic agents
- Evaluate clinical data on the safety, efficacy, and use of new agents for psoriasis
- Develop treatment strategies for difficult-to-manage psoriasis cases, including combination systemic therapy, transitioning to biologic agents, and transitioning between biologic agents
- Formulate a practical plan for the management of moderate to severe psoriasis, taking into consideration complex patient characteristics
Listed below is the faculty panel for the Ask the Expert section of PsoriasisTx.com. One faculty member has been selected to answer this Ask the Expert question based on his or her area of expertise.
David J. Cohen, MD
Chief, Division of Dermatology
Mercer University School of Medicine
Neil J. Korman, MD, PhD
Professor of Dermatology
Clinical Director, Murdough Family Center for Psoriasis
University Hospitals Case Medical Center
Steven C. Shapiro, MD
Director of Pediatric Dermatology and Staff Dermatologist
Departments of Pediatrics and Dermatology
Tulane Medical School
New Orleans, Louisiana
Jeffrey M. Weinberg, MD
Assistant Clinical Professor of Dermatology
Columbia University College of Physicians and Surgeons
Director, Clinical Research Center/Dermatopharmacology
St. Luke's-Roosevelt Hospital Center
New York, New York
Curatio CME Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Curatio CME Institute designates this educational activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in this CME activity. To receive credit during the period October 2009 to October 31, 2010, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, (3) complete the posttest, and (4) complete the activity evaluation form, including the certificate information section.
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
David J. Cohen, MD, has disclosed the following relevant financial relationships:
|Speaker||Abbott Laboratories, Amgen, Genentech|
Neil J. Korman, MD, PhD, has disclosed the following relevant financial relationships:
|Consultant/Advisory Board||Abbott, Astellas, Centocor, Genentech, Novartis, Peplin, Watson|
|Investigator||Abbott, Amgen, Astellas, Celgene, Centocor, Cytochroma, Genentech, Genmab, Kemia, Ligand, Merck, Novartis, Seattle Genetics|
|Speaker||Abbott, Amgen, Astellas, Genentech, Novartis|
Steven C. Shapiro, MD, has disclosed no relevant financial relationships.
Jeffrey M. Weinberg, MD, has disclosed the following relevant financial relationships:
|Speaker||Abbott, Amgen, Centocor, Genentech|
Curatio CME Institute
Shari J. Dermer, PhD, Medical Director, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.
Derek Warnick, CME Director, has disclosed no relevant financial relationships.
The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient's medical condition.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute and Genentech, Inc., do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute or Genentech, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
- High-speed Internet Browser
100 Campbell Boulevard
Exton, PA 19341
Policy on Privacy and Confidentiality
Curatio CME Institute makes every effort to protect the privacy of PsoriasisTx.com users; user information is used only to maintain records as required by the American Medical Association (AMA) and the ACCME.
Curatio CME Institute does not require individuals to register to use PsoriasisTx.com; registration is only required for physicians, health care professionals, and other users to participate in and receive CME/CE credit for accredited educational programs hosted on PsoriasisTx.com
Curatio CME Institute is required by the AMA and the ACCME (and occasionally by other accrediting organizations) to collect user information that will allow Curatio CME Institute to issue a CME/CE certificate. Curatio CME Institute is required to keep this information on file for up to 6 years. The information is stored in a secure database and used only to verify individual participation in a CME/CE activity and to reissue a certificate if a user's original certificate is lost or misplaced.
Information gathered through PsoriasisTx.com will not be released to any other company or organization for any purpose; this information remains confidential.
Curatio CME Institute uses Web site tracking software to determine how PsoriasisTx.com is used. This information helps Curatio CME Insitute determine the best strategies for improving PsoriasisTx.com and better meeting the needs of its users. This software does not identify individual users.
If you have any questions about PsoriasisTx.com or any Curatio CME Institute policies, you may contact us at email@example.com.
Thank you for using PsoriasisTx.com.